June 22, 2024
Investment

Arcus Biosciences: Did Gilead Sciences overpay for its latest investment? (NYSE:RCUS)


Earlier this week, Gilead Sciences (NASDAQ:GILD) raised its stake in Arcus Arcus Biosciences (NYSE:RCUS) to 33% from ~20% by making an additional equity investment of ~$320 million. The new share purchase came priced $21/share, compared to the $15.49 that RCUS shares were trading at on



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. View more
Accept
Decline